Circio ASA
€0
0
+€0+0% Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TA50.MU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec. The company has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. The company was incorporated in 2010 and is based in Oslo, Norway.
Show more...
CEO
Dr. Erik Digman Wiklund
Employees
9
Country
United Kingdom
ISIN
NO0013033795
Listings
0 Comments
Share your thoughts
FAQ
What is Circio ASA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Circio ASA stocks are traded under the ticker TA50.MU.
How many employees does Circio ASA have?▼
As of April 12, 2026, the company has 9 employees.
In which sector is Circio ASA located?▼
Circio ASA operates in the Energy sector.
When did Circio ASA complete a stock split?▼
Circio ASA has not had any recent stock splits.
Where is Circio ASA headquartered?▼
Circio ASA is headquartered in Oslo, United Kingdom.